In MYCN-amplified STA-NB-10 xenografts established in CD1:Foxn1nu/nu mice, continuous low-dose topotecan (0.1 mg/kg/day i.p. for 6 or 15 weeks) led to tumor regression and prolonged survival, with no evident toxicity. This evidence concerns the gene MYCN and neoplasm.